FGF21 Protects against Aggravated Blood-Brain Barrier Disruption after Ischemic Focal Stroke in Diabetic db/db Male Mice via Cerebrovascular PPARγ Activation

• Published in: International journal of molecular sciences 2020-01, Vol.21 (3), p.824
• Main Authors: Jiang, Yinghua, Lin, Li, Liu, Ning, Wang, Qingzhi, Yuan, Jing, Li, Yadan, Chung, Kelly K, Guo, Shuzhen, Yu, Zhanyang, Wang, Xiaoying
• Format: Article
• Language: English
• Subjects: Binding; Blood-brain barrier; Brain damage; Brain injury; CD36 antigen; Cerebral blood flow; Cerebrum; db/db mouse; Deoxyribonucleic acid; Diabetes; Diabetes mellitus; Diabetes mellitus (non-insulin dependent); DNA; Endothelial cells; Endothelium; Experiments; fibroblast growth factor 21; Fibroblast growth factor receptor 1; focal ischemic stroke; Gene expression; Growth factors; human brain microvascular endothelial cell; Hyperglycemia; Hypotheses; Inflammation; Injury prevention; Ischemia; Leakage; Microvasculature; Occlusion; Permeability; Protein expression; Proteins; Rodents; Stroke; type 2 diabetes
• ISSN: 1422-0067; 1661-6596; 1422-0067
• DOI: 10.3390/ijms21030824

Recombinant fibroblast growth factor 21 (rFGF21) has been shown to be potently beneficial for improving long-term neurological outcomes in type 2 diabetes mellitus (T2DM) stroke mice. Here, we tested the hypothesis that rFGF21 protects against poststroke blood-brain barrier (BBB) damage in T2DM mice via peroxisome proliferator-activated receptor gamma (PPARγ) activation in cerebral microvascular endothelium. We used the distal middle cerebral occlusion (dMCAO) model in T2DM mice as well as cultured human brain microvascular endothelial cells (HBMECs) subjected to hyperglycemic and inflammatory injury in the current study. We detected a significant reduction in PPARγ DNA-binding activity in the brain tissue and mRNA levels of BBB junctional proteins and PPARγ-targeting gene and in cerebral microvasculature at 24 h after stroke. Ischemic stroke induced a massive BBB leakage two days after stroke in T2DM mice compared to in their lean controls. Importantly, all abnormal changes were significantly prevented by rFGF21 administration initiated at 6 h after stroke. Our in vitro experimental results also demonstrated that rFGF21 protects against hyperglycemia plus interleukin (IL)-1β-induced transendothelial permeability through upregulation of junction protein expression in an FGFR1 activation and PPARγ activity elevation-dependent manner. Our data suggested that rFGF21 has strong protective effects on acute BBB leakage after diabetic stroke, which is partially mediated by increasing PPARγ DNA-binding activity and mRNA expression of BBB junctional complex proteins. Together with our previous investigations, rFGF21 might be a promising candidate for treating diabetic stroke.